A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Inclusion Criteria: Age ≥18 and ≤70 years old, regardless of gender; Patients with head and neck squamous carcinoma who are pathologically confirmed and fulfill the following conditions: Patients with locally advanced head and neck squamous carcinoma (excluding nasopharyngeal, salivary gland and thyroid malignant tumors) who are initially diagnosed and have no distant metastasis; Non oropharyngeal HNSCC carcinoma and HPV-negative oropharyngeal carcinoma, stages III, IVA and IVB; HPV-positive oropharyngeal cancers, stages II and III; HPV status of oropharyngeal cancer will be determined by p16 immunohistochemistry. Treatable by surgical resection as evaluated by head and neck surgery; Definite lymph node metastasis and lymph node stage is not N0 or Nx. An Eastern Cooperative Oncology Group (ECOG) physical status score of 0 to 1; Have adequate organ and bone marrow function as defined below: Subjects voluntarily enrolled in the study, signed an informed consent form, and were able to comply with the visits and related procedures specified in the protocol. Exclusion Criteria: Lymph node staging of N0 or Nx status; History of other malignancies (except history of cured and non-recurrent basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical cancer in situ, intramucosal carcinoma of the gastrointestinal tract, and other malignancies considered by the investigator to be eligible for enrollment); Any active autoimmune dis…